
CLAIMS

What is claimed is:

1. A compound of Formula (I):


(I)

or stereoisomers, tautomer, solvates or salts thereof, wherein:


(i) X is C-A and Y is N; and Q_1 is G and Q_2 is R_3;


(ii) X is N and Y is C-A; and Q_1 is G and Q_2 is R_3; or

(iii) X is N and Y is C-A; and Q_1 is R_3 and Q_2 is G;


G is:


(i) phenyl substituted with 1 to 3 substituents independently selected from $–OCH_3$, $–S(O)_2CH_3$, $–S(O)_2N(CH_3)_2$, $–S(O)_2$(cyclopropyl), and $–S(O)(NH)N(CH_3)_2$;


(ii)  ;


(iii)  ;

(iv) a 9-membered heterocyclic ring selected from:










and ; or

(v) 10-membered heterocyclic ring selected from:



and ;

A is piperidinyl, phenyl, pyridinyl, pyrimidinyl, 6-azabicyclo[3.2.1]octanyl, or azabicyclo[3.2.1]octanyl, each substituted with $-L-R_4$ and zero to 2 R_{4b};

L is a bond, $-CR_xR_x-$, or $-C(O)(CR_xR_x)_{0-2}-$;

R_1 is hydrogen, C_{1-3} alkyl, C_{1-2} fluoroalkyl, or C_{3-4} cycloalkyl;

each R_2 is independently halo, $-CN$, $-OH$, $-NO_2$, C_{1-4} alkyl, C_{1-2} fluoroalkyl, C_{1-2} cyanoalkyl, C_{1-3} hydroxyalkyl, C_{1-3} aminoalkyl, $-O(CH_2)_{1-2}OH$, $-(CH_2)_{0-4}O(C_{1-4}$ alkyl), C_{1-3} fluoroalkoxy, $-(CH_2)_{1-4}O(C_{1-3}$ alkyl), $-O(CH_2)_{1-2}OC(O)(C_{1-3}$ alkyl), $-O(CH_2)_{1-2}NR_xR_x$, $-C(O)O(C_{1-3}$ alkyl), $-(CH_2)_{0-2}C(O)NR_yR_y$, $-C(O)NR_x(C_{1-5}$ hydroxyalkyl), $-C(O)NR_x(C_{2-6}$ alkoxyalkyl), $-C(O)NR_x(C_{3-6}$ cycloalkyl), $-NR_yR_y$, $-NR_y(C_{1-3}$ fluoroalkyl), $-NR_y(C_{1-4}$ hydroxyalkyl), $-NR_xCH_2$(phenyl), $-NR_xS(O)_2(C_{3-6}$ cycloalkyl), $-NR_xC(O)(C_{1-3}$ alkyl), $-NR_xCH_2(C_{3-6}$ cycloalkyl), $-S(O)_2(C_{1-3}$ alkyl), $-S(O)_2N(C_{1-3}$ alkyl)$_2$, $-S(O)(NH)N(C_{1-3}$ alkyl)$_2$, $-(CH_2)_{0-2}(C_{3-6}$ cycloalkyl), $-(CH_2)_{0-2}$(phenyl), morpholinyl, dioxothiomorpholinyl, dimethyl pyrazolyl, methylpiperidinyl, methylpiperazinyl, amino-oxadiazolyl, imidazolyl, triazolyl, or $-C(O)$(thiazolyl);

R_{2a} is C_{1-6} alkyl, C_{1-3} fluoroalkyl, C_{1-6} hydroxyalkyl, C_{1-3} aminoalkyl, $-(CH_2)_{0-4}O(C_{1-3}$ alkyl), C_{3-6} cycloalkyl, $-(CH_2)_{1-3}C(O)NR_xR_x$, $-CH_2(C_{3-6}$ cycloalkyl), $-CH_2$(phenyl), tetrahydrofuranyl, tetrahydropyranyl, or phenyl;

each R_{2b} is independently H, halo, –CN, $-NR_xR_x$, C_{1-6} alkyl, C_{1-3} fluoroalkyl, C_{1-3} hydroxyalkyl, C_{1-3} fluoroalkoxy, $-(CH_2)_{0-2}O(C_{1-3}$ alkyl), $-(CH_2)_{0-3}C(O)NR_xR_x$, $-(CH_2)_{1-3}(C_{3-6}$ cycloalkyl), $-C(O)O(C_{1-3}$ alkyl), $-C(O)NR_x(C_{1-3}$ alkyl), $-CR_x=CR_xR_x$, or $-CR_x=CH(C_{3-6}$ cycloalkyl);

R_{2c} is R_{2a} or R_{2b};


R_{2d} is R_{2a} or R_{2b}; provided that one of R_{2c} and R_{2d} is R_{2a}, and the other of R_{2c} and R_{2d} is R_{2b};

R_3 is hydrogen, F, C_{1-3} alkyl, or C_{3-4} cycloalkyl;

R_4 is:

(i) $-N(CH_3)_2$;

(ii) morpholinyl, pyrrolidinyl, piperidinyl, piperazinyl, pyridinyl, dioxothiomorpholinyl, azaspiro[3.3]heptanyl, azabicyclo[3.2.1]octanyl, diazabicyclo[2.2.2]octanyl, or diazabicyclo[3.2.1]octanyl, each substituted with zero to 4 R_{4a}; or

(iii) 

;

each R_{4a} is independently –OH, C_{1-6} alkyl, C_{1-3} fluoroalkyl, C_{3-6} cycloalkyl, $-CH_2(C_{3-6}$ cycloalkyl), $-C(O)(C_{1-4}$ alkyl), $-C(O)(C_{3-6}$ cycloalkyl), –C(O)(phenyl), $-C(O)CH_2(C_{3-6}$ cycloalkyl), $-C(O)CH_2$(phenyl), or $-C(O)O(C_{1-4}$ alkyl);

each R_{4b} is independently F, Cl, or $-CH_3$;

each R_{4c} is independently –OH, C_{1-6} alkyl, C_{1-3} fluoroalkyl, $-CH_2(C_{3-6}$ cycloalkyl), $-C(O)(C_{1-4}$ alkyl), –C(O)(phenyl), $-C(O)CH_2$(phenyl), $-C(O)OCH_2CH_3$, or C_{3-6} cycloalkyl;

each R_5 is independently hydrogen, F, Cl, C_{1-3} alkyl, C_{1-3} hydroxyalkyl, C_{1-3} alkoxy, cyclopropyl, or morpholinyl;

each R_x is independently H or $–CH_3$;


each R_y is independently H or $C_{1–6}$ alkyl;

m is zero, 1, or 2;

n is zero, 1, or 2; and


p is zero, 1, 2, 3, or 4.

2. The compound according to claim 1 or stereoisomers, tautomer, solvates or salts thereof, having the structure of Formula (III):




(III).

3. The compound according to claim 1 or stereoisomers, tautomer, solvates or salts thereof, having the structure of Formula (IIIb):



(IIIb).

4. The compound according to claim 1 or stereoisomers, tautomer, solvates or salts thereof, having the structure of Formula (IIa):



(IIa).

5. The compound according to claim 1 or stereoisomers, tautomer, solvates or salts thereof, or a salt thereof, wherein:

G is phenyl substituted with 1 to 2 substituents independently selected from $-OCH_3$, $-S(O)_2CH_3$, $-S(O)_2N(CH_3)_2$, and $-S(O)_2$(cyclopropyl);

A is piperidinyl, phenyl, or pyridinyl, each substituted with $-L-R_4$ and zero to 2 R_{4b};

L is a bond, $-CH_2-$, $-C(O)-$, $-C(O)CH_2-$, or $-C(O)CH_2CH_2-$;

R_1 is hydrogen, $-CH_3$, $-CHF_2$, or cyclopropyl;

R_3 is hydrogen, F, $-CH_3$, or cyclopropyl;

R_4 is:

(i) $-N(CH_3)_2$; or

(ii) pyrrolidinyl, piperidinyl, piperazinyl, or pyridinyl, each substituted with zero to 4 R_{4a};

each R_{4a} is independently $-OH$, C_{1-6} alkyl, C_{1-3} fluoroalkyl, $-CH_2(C_{3-6}$ cycloalkyl), $-C(O)(C_{1-4}$ alkyl), $-C(O)$(phenyl), $-C(O)CH_2$(phenyl), $-C(O)OCH_2CH_3$, or C_{3-6} cycloalkyl;

each R_{4b} is independently F, Cl, or $-CH_3$;

each R_{4c} is independently C_{1-6} alkyl, C_{1-3} fluoroalkyl, $-CH_2(C_{3-6}$ cycloalkyl), $-C(O)(C_{1-4}$ alkyl), $-C(O)$(phenyl), $-C(O)CH_2$(phenyl), $-C(O)OCH_2CH_3$, or C_{3-6} cycloalkyl;

each R_5 is independently hydrogen, F, Cl, C_{1-3} alkyl, C_{1-3} hydroxyalkyl, C_{1-2} alkoxy, cyclopropyl, or morpholinyl;

m is zero, 1, or 2; and

n is zero, 1, or 2.

6. The compound according to claim 1 or stereoisomers, tautomer, solvates or salts thereof, wherein:

G is phenyl substituted with 1 to 2 substituents independently selected from $-OCH_3$, $-S(O)_2CH_3$, $-S(O)_2N(CH_3)_2$, and $-S(O)_2$(cyclopropyl);

A is piperidinyl, phenyl, or pyridinyl, each substituted with $-L-R_4$ and zero to 2 R_{4b};

L is a bond, $-CH_2-$, $-C(O)-$, $-C(O)CH_2-$, or $-C(O)CH_2CH_2-$;

R_1 is hydrogen or $-CH_3$;

R_3 is hydrogen, F, $-CH_3$, or cyclopropyl;

R_4 is:

(i) $-N(CH_3)_2$; or

(ii) pyrrolidinyl, piperidinyl, piperazinyl, or pyridinyl, each substituted with zero to 4 R_{4a};

each R_{4a} is independently $-OH$, $-CH_3$, $-CHCH_3$, $-CH(CH_3)_2$, $-CH_2CH(CH_3)_2$, $-C(CH_3)_3$, $-CH_2C(CH_3)_3$, $-CH_2CH_2C(CH_3)_3$, $-CF_3$, $-CH_2CH_2OH$, $-CH_2CH_2CH_2OH$, $-CH_2C(CH_3)_2OH$, $-CH_2CH_2C(CH_3)_2OH$, $-CH_2CH_2OCH_3$, $-CH_2$(cyclopropyl), $-C(O)CH_3$, $-C(O)CH(CH_3)_2$, $-C(O)CH_2CH_3$, $-C(O)$(phenyl), $-C(O)CH_2$(phenyl), $-C(O)OCH_2CH_3$, $-C(O)O$(phenyl), cyclopropyl, cyclobutyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, $-(CH_2)_{1-2}$(bromophenyl), or $-(CH_2)_{1-2}$(iodophenyl);

each R_{4b} is F; and

each R_5 is independently hydrogen, $-CH_3$, $-C(CH_3)_2OH$, $-OCH_3$, or morpholinyl.

7. The compound according to claim 1 or stereoisomers, tautomer, solvates or salts thereof, wherein:

G is phenyl substituted with 1 to 2 substituents independently selected from $-OCH_3$, $-S(O)_2CH_3$, $-S(O)_2N(CH_3)_2$, and $-S(O)_2$(cyclopropyl);

A is piperidinyl, phenyl, or pyridinyl, each substituted with $-L-R_4$ and zero to 2 R_{4b};

L is a bond, $-CH_2-$, $-C(O)-$, $-C(O)CH_2-$, or $-C(O)CH_2CH_2-$;

R_1 is hydrogen or $-CH_3$;

R_3 is hydrogen, F, $-CH_3$, or cyclopropyl;

R_4 is:

(i) $-N(CH_3)_2$; or

(ii) pyrrolidinyl, piperidinyl, piperazinyl, or pyridinyl, each substituted with zero to 4 R_{4a};

each R_{4a} is independently $-OH$, $-CH_3$, $-CHCH_3$, $-CH(CH_3)_2$, $-CH_2CH(CH_3)_2$, $-C(CH_3)_3$, $-CH_2C(CH_3)_3$, $-CH_2CH_2C(CH_3)_3$, $-CF_3$, $-CH_2CH_2OH$, $-CH_2CH_2CH_2OH$, $-CH_2C(CH_3)_2OH$, $-CH_2CH_2C(CH_3)_2OH$, $-CH_2CH_2OCH_3$, $-CH_2$(cyclopropyl),

–C(O)CH_3, –C(O)$CH(CH_3)_2$, –C(O)CH_2CH_3, –C(O)(phenyl), –C(O)CH_2(phenyl), –C(O)OCH_2CH_3, –C(O)O(phenyl), cyclopropyl, cyclobutyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, –$(CH_2)_{1–2}$(bromophenyl), or –$(CH_2)_{1–2}$(iodophenyl);

each R_{4b} is F; and

each R_5 is independently hydrogen, –CH_3, –$C(CH_3)_2OH$, –OCH_3, or morpholinyl.

8. The compound according to claim 1 or stereoisomers, tautomer, solvates or salts thereof, wherein:

X is N;

Y is C-A;

Q_1 is R_3;

Q_2 is G;

G is phenyl substituted with 1 to 2 substituents independently selected from –OCH_3, –$S(O)_2CH_3$, –$S(O)_2N(CH_3)_2$, and –$S(O)_2$(cyclopropyl);


A is piperidinyl or phenyl, each substituted with –L–R_4 and zero to 2 R_{4b};

L is a bond, –CH_2–, or –C(O)CH_2–;

R_1 is –CH_3;

R_3 is hydrogen, F, or cyclopropyl;

R_4 is morpholinyl, piperidinyl, piperazinyl, pyridinyl, dioxothiomorpholinyl, azabicyclo[3.2.1]octanyl, diazabicyclo[2.2.2]octanyl, or diazabicyclo[3.2.1]octanyl, each substituted with zero to 4 R_{4a}; or

(iii) 

;

each substituted with zero to 4 R_{4a};

each R_{4a} is independently –OH, –CH_3, –$CHCH_3$, –$CH(CH_3)_2$, –$CH_2CH(CH_3)_2$, –$C(CH_3)_3$, –CF_3, –CH_2CH_2OH, –$CH_2CH_2CH_2OH$, –$CH_2C(CH_3)_2OH$, –$CH_2CH_2C(CH_3)_2OH$, –$CH_2CH_2OCH_3$, –CH_2(cyclopropyl), –C(O)CH_3, –C(O)(phenyl), –C(O)OCH_2CH_3, cyclopropyl, cyclobutyl, oxetanyl,

tetrahydrofuranyl, tetrahydropyranyl, $-(CH_2)_{1-2}$(bromophenyl), or $-(CH_2)_{1-2}$(iodophenyl);

each R_{4b} is F; and

each R_5 is independently hydrogen, $-CH_3$, $-C(CH_3)_2OH$, $-OCH_3$, or morpholinyl.

9. The compound according to claim 1 or stereoisomers, tautomer, solvates or salts thereof, wherein said compound is:

2-(3,4-dimethoxyphenyl)-5-(4-(4-isopropylpiperazin-1-yl)phenyl)-3-methyl-1H-pyrrolo[2,3-c]pyridine (2);

1-(4-(4-(3-(3,4-dimethoxyphenyl)-1,2-dimethyl-1H-pyrrolo[2,3-c]pyridin-5-yl) phenyl)piperazin-1-yl)-2-methylpropan-2-ol (3);

benzyl 4-(3-(3,4-dimethoxyphenyl)-2-methyl-1H-pyrrolo[2,3-c]pyridin-5-yl)-[1,4'-bipiperidine]-1'-carboxylate (4);

(1-cyclopropylpiperidin-4-yl)(4-(3-(3,4-dimethoxyphenyl)-2-methyl-1H-pyrrolo[2,3-c]pyridin-5-yl)piperidin-1-yl)methanone (5);

3-(3,4-dimethoxyphenyl)-5-(1-(2,6-dimethylpyridin-4-yl)piperidin-4-yl)-2-methyl-1H-pyrrolo[2,3-c]pyridine (6);

ethyl 4-(2-(3,4-dimethoxyphenyl)-1-methyl-1H-pyrrolo[3,2-c]pyridin-6-yl)-[1,4'-bipiperidine]-1'-carboxylate (7);

2-(3,4-dimethoxyphenyl)-1-methyl-6-(1-((6-methylpyridin-3-yl)methyl)piperidin-4-yl)-1H-pyrrolo[3,2-c]pyridine (8);

6-(4-(4-(cyclopropylmethyl)piperazin-1-yl)phenyl)-2-(3,4-dimethoxyphenyl)-1-methyl-1H-pyrrolo[3,2-c]pyridine (9);

6-(4-(4-cyclobutylpiperazin-1-yl)phenyl)-2-(3,4-dimethoxyphenyl)-1-methyl-1H-pyrrolo[3,2-c]pyridine (10);

6-(4-(4-isopropylpiperazin-1-yl)phenyl)-1,4-dimethyl-2-(4-(methylsulfonyl)phenyl)-1H-pyrrolo[3,2-c]pyridine (11);

6-(3-fluoro-4-(4-isopropylpiperazin-1-yl)phenyl)-1,4-dimethyl-2-(4-(methylsulfonyl)phenyl)-1H-pyrrolo[3,2-c]pyridine (12);

(4-(3-(3,4-dimethoxyphenyl)-2-methyl-1H-pyrrolo[2,3-c]pyridin-5-yl)-[1,4'-bipiperidin]-1'-yl)(phenyl)methanone (14);

1-(4-(3-(3,4-dimethoxyphenyl)-2-methyl-1H-pyrrolo[2,3-c]pyridin-5-yl)-[1,4'-bipiperidin]-1'-yl)-2-methylpropan-1-one (15);

1-(4-(3-(3,4-dimethoxyphenyl)-2-methyl-1H-pyrrolo[2,3-c]pyridin-5-yl)piperidin-1-yl)-2-(piperidin-1-yl)ethan-1-one (16);

3-(3,4-dimethoxyphenyl)-5-(1'-isobutyl-[1,4'-bipiperidin]-4-yl)-1,2-dimethyl-1H-pyrrolo[2,3-c]pyridine (17);

1-(4-(3-(3,4-dimethoxyphenyl)-1,2-dimethyl-1H-pyrrolo[2,3-c]pyridin-5-yl)-[1,4'-bipiperidin]-1'-yl)-2-methylpropan-1-one (18);

(4-(3-(3,4-dimethoxyphenyl)-1,2-dimethyl-1H-pyrrolo[2,3-c]pyridin-5-yl)-[1,4'-bipiperidin]-1'-yl)(phenyl)methanone (19);

ethyl 4-(3-(3,4-dimethoxyphenyl)-1,2-dimethyl-1H-pyrrolo[2,3-c]pyridin-5-yl)-[1,4'-bipiperidine]-1'-carboxylate (20);

1-(4-(3-(3,4-dimethoxyphenyl)-2-methyl-1H-pyrrolo[2,3-c]pyridin-5-yl)piperidin-1-yl)-2-(pyrrolidin-1-yl)ethan-1-one (21);

1-(4-(3-(3,4-dimethoxyphenyl)-2-methyl-1H-pyrrolo[2,3-c]pyridin-5-yl)piperidin-1-yl)-2-(dimethylamino)ethan-1-one (22);

1-(4-(3-(3,4-dimethoxyphenyl)-2-methyl-1H-pyrrolo[2,3-c]pyridin-5-yl)piperidin-1-yl)-3-(pyrrolidin-1-yl)propan-1-one (23);

2-(3,4-dimethoxyphenyl)-6-(4-(4-isopropylpiperazin-1-yl)phenyl)-1-methyl-1H-pyrrolo[3,2-c]pyridine (24);

1-(4-(2-(3,4-dimethoxyphenyl)-1-methyl-1H-pyrrolo[3,2-c]pyridin-6-yl)piperidin-1-yl)-2-(piperidin-1-yl)ethan-1-one (25);

(4-(2-(3,4-dimethoxyphenyl)-1-methyl-1H-pyrrolo[3,2-c]pyridin-6-yl)-[1,4'-bipiperidin]-1'-yl)(phenyl)methanone (26);

2-(3,4-dimethoxyphenyl)-1-methyl-6-(4-(4-methylpiperazin-1-yl)phenyl)-1H-pyrrolo[3,2-c]pyridine (27);

2-(3,4-dimethoxyphenyl)-1-methyl-6-(1-((6-(trifluoromethyl)pyridin-3-yl)methyl) piperidin-4-yl)-1H-pyrrolo[3,2-c]pyridine (28);

(4-(4-(2-(3,4-dimethoxyphenyl)-1-methyl-1H-pyrrolo[3,2-c]pyridin-6-yl)phenyl) piperazin-1-yl)(phenyl)methanone (29);

1-(4-(4-(2-(3,4-dimethoxyphenyl)-1-methyl-1H-pyrrolo[3,2-c]pyridin-6-yl)phenyl) piperazin-1-yl)ethan-1-one (30);

2-(3,4-dimethoxyphenyl)-6-(6-(4-isopropylpiperazin-1-yl)pyridin-3-yl)-1-methyl-1H-pyrrolo[3,2-c]pyridine (31);

3-(3,4-dimethoxyphenyl)-5-(4-(4-isopropylpiperazin-1-yl)phenyl)-1,2-dimethyl-1H-pyrrolo[2,3-c]pyridine (32);

4-(4-(4-(3-(3,4-dimethoxyphenyl)-1,2-dimethyl-1H-pyrrolo[2,3-c]pyridin-5-yl) phenyl)piperazin-1-yl)-2-methylbutan-2-ol (33);

6-(4-(4-isobutylpiperazin-1-yl)phenyl)-1,4-dimethyl-2-(4-(methylsulfonyl)phenyl)-1H-pyrrolo[3,2-c]pyridine (34);

1,4-dimethyl-2-(4-(methylsulfonyl)phenyl)-6-(4-(4-(tetrahydro-2H-pyran-4-yl) piperazin-1-yl)phenyl)-1H-pyrrolo[3,2-c]pyridine (35);

3-(4-(4-(1,4-dimethyl-2-(4-(methylsulfonyl)phenyl)-1H-pyrrolo[3,2-c]pyridin-6-yl) phenyl)piperazin-1-yl)propan-1-ol (36);

1,4-dimethyl-2-(4-(methylsulfonyl)phenyl)-6-(4-(4-(tetrahydrofuran-3-yl)piperazin-1-yl)phenyl)-1H-pyrrolo[3,2-c]pyridine (37);

6-(4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)-1,4-dimethyl-2-(4-(methylsulfonyl) phenyl)-1H-pyrrolo[3,2-c]pyridine (38);

6-(4-(4-isopropylpiperazin-1-yl)phenyl)-1,4-dimethyl-2-(3-(methylsulfonyl)phenyl)-1H-pyrrolo[3,2-c]pyridine (39);

6-(4-(4-isobutylpiperazin-1-yl)phenyl)-1,4-dimethyl-2-(3-(methylsulfonyl)phenyl)-1H-pyrrolo[3,2-c]pyridine (40);

3-(4-(4-(1,4-dimethyl-2-(4-(methylsulfonyl)phenyl)-1H-pyrrolo[3,2-c]pyridin-6-yl) phenyl)piperidin-1-yl)propan-1-ol (41);

2-(4-(cyclopropylsulfonyl)phenyl)-6-(4-(4-isopropylpiperazin-1-yl)phenyl)-1,4-dimethyl-1H-pyrrolo[3,2-c]pyridine (42);

6-(2,5-difluoro-4-(piperazin-1-yl)phenyl)-1,4-dimethyl-2-(4-(methylsulfonyl) phenyl)-1H-pyrrolo[3,2-c]pyridine (43);

1-(4-(4-(1,4-dimethyl-2-(4-(methylsulfonyl)phenyl)-1H-pyrrolo[3,2-c]pyridin-6-yl) benzyl)piperazin-1-yl)-2-methylpropan-2-ol (44);

3-((1R,4R)-5-(4-(1,4-dimethyl-2-(4-(methylsulfonyl)phenyl)-1H-pyrrolo[3,2-c] pyridin-6-yl)benzyl)-2,5-diazabicyclo[2.2.2]octan-2-yl)-2,2-dimethylpropan-1-ol (45);

2-(4-(cyclopropylsulfonyl)phenyl)-6-(4-(4-isobutylpiperazin-1-yl)phenyl)-1,4-dimethyl-1H-pyrrolo[3,2-c]pyridine (46);

3-(4-(4-(2-(4-(cyclopropylsulfonyl)phenyl)-1,4-dimethyl-1H-pyrrolo[3,2-c]pyridin-6-yl)phenyl)piperazin-1-yl)propan-1-ol (47);

2-(4-(cyclopropylsulfonyl)phenyl)-6-(4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)-1,4-dimethyl-1H-pyrrolo[3,2-c]pyridine (48);

4-(6-(4-(4-isopropylpiperazin-1-yl)phenyl)-1,4-dimethyl-1H-pyrrolo[3,2-c]pyridin-2-yl)-N,N-dimethylbenzenesulfonamide (49);

4-(1,4-dimethyl-6-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)-1H-pyrrolo[3,2-c] pyridin-2-yl)-N,N-dimethylbenzenesulfonamide (50);

4-(6-(4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)-1,4-dimethyl-1H-pyrrolo[3,2-c] pyridin-2-yl)-N,N-dimethylbenzenesulfonamide (51);

4-(1,4-dimethyl-6-(4-(4-(tetrahydrofuran-3-yl)piperazin-1-yl)phenyl)-1H-pyrrolo[3,2-c]pyridin-2-yl)-N,N-dimethylbenzenesulfonamide (52);

6-(4-(4-isobutylpiperazin-1-yl)phenyl)-1-methyl-2-(4-(methylsulfonyl)phenyl)-1H-pyrrolo[3,2-c]pyridine (53);

6-(4-(4-isopropylpiperazin-1-yl)phenyl)-1-methyl-2-(4-(methylsulfonyl)phenyl)-1H-pyrrolo[3,2-c]pyridine (54);

3-(4-(4-(1,4-dimethyl-2-(4-(methylsulfonyl)phenyl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-2,3-difluorophenyl)piperazin-1-yl)propan-1-ol (55);

3-(4-(4-(1,4-dimethyl-2-(4-(methylsulfonyl)phenyl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-2,5-difluorophenyl)piperazin-1-yl)propan-1-ol (56);

6-(4-((4-isobutylpiperazin-1-yl)methyl)phenyl)-1,4-dimethyl-2-(4-(methylsulfonyl) phenyl)-1H-pyrrolo[3,2-c]pyridine (57);

3-(4-(4-(1,4-dimethyl-2-(4-(methylsulfonyl)phenyl)-1H-pyrrolo[3,2-c]pyridin-6-yl) benzyl)piperazin-1-yl)propan-1-ol (58);

1-(4-(1,4-dimethyl-2-(4-(methylsulfonyl)phenyl)-1H-pyrrolo[3,2-c]pyridin-6-yl) benzyl)-4-methylpiperidin-4-ol (59);

4-(4-(4-(1,4-dimethyl-2-(4-(methylsulfonyl)phenyl)-1H-pyrrolo[3,2-c]pyridin-6-yl) benzyl)piperazin-1-yl)-2-methylbutan-2-ol (60);

4-((1S,4S)-5-(4-(1,4-dimethyl-2-(4-(methylsulfonyl)phenyl)-1H-pyrrolo[3,2-c] pyridin-6-yl)benzyl)-2,5-diazabicyclo[2.2.2]octan-2-yl)-2-methylbutan-2-ol (61);

6-(4-(4-cyclopropylpiperazin-1-yl)phenyl)-1,4-dimethyl-2-(4-(methylsulfonyl) phenyl)-1H-pyrrolo[3,2-c]pyridine (62);

6-(4-(hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)phenyl)-1,4-dimethyl-2-(4-(methylsulfonyl)phenyl)-1H-pyrrolo[3,2-c]pyridine (63);

6-(4-(8-isopropyl-3,8-diazabicyclo[3.2.1]octan-3-yl)phenyl)-1,4-dimethyl-2-(4-(methylsulfonyl)phenyl)-1H-pyrrolo[3,2-c]pyridine (64);

6-(3-fluoro-4-(hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)phenyl)-1,4-dimethyl-2-(4-(methylsulfonyl)phenyl)-1H-pyrrolo[3,2-c]pyridine (65);

6-(3-fluoro-4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)-1,4-dimethyl-2-(4-(methylsulfonyl)phenyl)-1H-pyrrolo[3,2-c]pyridine (66);

6-(3-(4-isopropylpiperazin-1-yl)phenyl)-1,4-dimethyl-2-(4-(methylsulfonyl)phenyl)-1H-pyrrolo[3,2-c]pyridine (67);

6-(3-(4-cyclopropylpiperazin-1-yl)phenyl)-1,4-dimethyl-2-(4-(methylsulfonyl) phenyl)-1H-pyrrolo[3,2-c]pyridine (68);

2-(4-(4-(1,4-dimethyl-2-(4-(methylsulfonyl)phenyl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-2-fluorophenyl)piperazin-1-yl)ethan-1-ol (69);

6-(3-fluoro-4-(4-(tetrahydrofuran-3-yl)piperazin-1-yl)phenyl)-1,4-dimethyl-2-(4-(methylsulfonyl)phenyl)-1H-pyrrolo[3,2-c]pyridine (70);

6-(3-fluoro-4-(4-(tetrahydro-2H-pyran-4-yl)piperazin-1-yl)phenyl)-1,4-dimethyl-2-(4-(methylsulfonyl)phenyl)-1H-pyrrolo[3,2-c]pyridine (71);

6-(3-fluoro-4-(4-isobutylpiperazin-1-yl)phenyl)-1,4-dimethyl-2-(4-(methylsulfonyl) phenyl)-1H-pyrrolo[3,2-c]pyridine (72);

6-(4-(8-isobutyl-3,8-diazabicyclo[3.2.1]octan-3-yl)phenyl)-1,4-dimethyl-2-(4-(methylsulfonyl)phenyl)-1H-pyrrolo[3,2-c]pyridine (73);

6-(4-(8-(2-methoxyethyl)-3,8-diazabicyclo[3.2.1]octan-3-yl)phenyl)-1,4-dimethyl-2-(4-(methylsulfonyl)phenyl)-1H-pyrrolo[3,2-c]pyridine (74);

6-(3-fluoro-4-(8-(2-methoxyethyl)-3,8-diazabicyclo[3.2.1]octan-3-yl)phenyl)-1,4-dimethyl-2-(4-(methylsulfonyl)phenyl)-1H-pyrrolo[3,2-c]pyridine (75);

3-(3-(4-(1,4-dimethyl-2-(4-(methylsulfonyl)phenyl)-1H-pyrrolo[3,2-c]pyridin-6-yl)phenyl)-3,8-diazabicyclo[3.2.1]octan-8-yl)propan-1-ol (76);

3-(3-(4-(1,4-dimethyl-2-(4-(methylsulfonyl)phenyl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-2-fluorophenyl)-3,8-diazabicyclo[3.2.1]octan-8-yl)propan-1-ol (77);

6-(2,5-difluoro-4-(8-(2-methoxyethyl)-3,8-diazabicyclo[3.2.1]octan-3-yl)phenyl)-1,4-dimethyl-2-(4-(methylsulfonyl)phenyl)-1H-pyrrolo[3,2-c]pyridine (78);

3-(3-(4-(1,4-dimethyl-2-(4-(methylsulfonyl)phenyl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-2,5-difluorophenyl)-3,8-diazabicyclo[3.2.1]octan-8-yl)propan-1-ol (79-80);

6-(2,5-difluoro-4-(4-(tetrahydro-2H-pyran-4-yl)piperazin-1-yl)phenyl)-1,4-dimethyl-2-(4-(methylsulfonyl)phenyl)-1H-pyrrolo[3,2-c]pyridine (81);

6-(2,3-difluoro-4-(4-isobutylpiperazin-1-yl)phenyl)-1,4-dimethyl-2-(4-(methylsulfonyl)phenyl)-1H-pyrrolo[3,2-c]pyridine (82);

6-(2,3-difluoro-4-(4-(tetrahydro-2H-pyran-4-yl)piperazin-1-yl)phenyl)-1,4-dimethyl-2-(4-(methylsulfonyl)phenyl)-1H-pyrrolo[3,2-c]pyridine (83);

6-(3,5-difluoro-4-(4-isobutylpiperazin-1-yl)phenyl)-1,4-dimethyl-2-(4-(methylsulfonyl)phenyl)-1H-pyrrolo[3,2-c]pyridine (84);

4-(4-(1,4-dimethyl-2-(4-(methylsulfonyl)phenyl)-1H-pyrrolo[3,2-c]pyridin-6-yl)phenyl)thiomorpholine 1,1-dioxide (85);

4-(4-(1,4-dimethyl-2-(4-(methylsulfonyl)phenyl)-1H-pyrrolo[3,2-c]pyridin-6-yl)phenyl)morpholine (86);

1-cyclopropyl-4-(4-(1,4-dimethyl-2-(4-(methylsulfonyl)phenyl)-1H-pyrrolo[3,2-c]pyridin-6-yl)phenyl)piperidin-4-ol (87);

4-(4-(1,4-dimethyl-2-(4-(methylsulfonyl)phenyl)-1H-pyrrolo[3,2-c]pyridin-6-yl)phenyl)-1-isopropylpiperidin-4-ol (88);

6-(3,5-difluoro-4-(4-(tetrahydro-2H-pyran-4-yl)piperazin-1-yl)phenyl)-1,4-dimethyl-2-(4-(methylsulfonyl)phenyl)-1H-pyrrolo[3,2-c]pyridine (89);

4-(4-(1,4-dimethyl-2-(4-(methylsulfonyl)phenyl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-2-fluorophenyl)-1-isobutylpiperidin-4-ol (90);

(1R,3r,5S)-3-(4-(1,4-dimethyl-2-(4-(methylsulfonyl)phenyl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-2-fluorophenyl)-8-isobutyl-8-azabicyclo[3.2.1]octan-3-ol (91);

4-(4-(1,4-dimethyl-2-(4-(methylsulfonyl)phenyl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-2-fluorophenyl)-1-(2-methoxyethyl)piperidin-4-ol (92);

1-cyclopropyl-4-(4-(1,4-dimethyl-2-(4-(methylsulfonyl)phenyl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-2-fluorophenyl)piperidin-4-ol (93);

4-(4-(1,4-dimethyl-2-(4-(methylsulfonyl)phenyl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-2,5-difluorophenyl)-1-isobutylpiperidin-4-ol (94);

4-(4-(1,4-dimethyl-2-(4-(methylsulfonyl)phenyl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-2,5-difluorophenyl)-1-(2-methoxyethyl)piperidin-4-ol (95);

1-cyclopropyl-4-(4-(1,4-dimethyl-2-(4-(methylsulfonyl)phenyl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-2,5-difluorophenyl)piperidin-4-ol (96);

6-(2,5-difluoro-4-(hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)phenyl)-1,4-dimethyl-2-(4-(methylsulfonyl)phenyl)-1H-pyrrolo[3,2-c]pyridine (97);

6-(3,5-difluoro-4-(hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)phenyl)-1,4-dimethyl-2-(4-(methylsulfonyl)phenyl)-1H-pyrrolo[3,2-c]pyridine (98);

6-(2,3-difluoro-4-(hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)phenyl)-1,4-dimethyl-2-(4-(methylsulfonyl)phenyl)-1H-pyrrolo[3,2-c]pyridine (99);

(1R,3r,5S)-3-(4-(1,4-dimethyl-2-(4-(methylsulfonyl)phenyl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-2-fluorophenyl)-8-isopropyl-8-azabicyclo[3.2.1]octan-3-ol (100);

(1R,3r,5S)-3-(4-(1,4-dimethyl-2-(4-(methylsulfonyl)phenyl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-2-fluorophenyl)-8-ethyl-8-azabicyclo[3.2.1]octan-3-ol (101);

(1R,3r,5S)-3-(4-(1,4-dimethyl-2-(4-(methylsulfonyl)phenyl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-2-fluorophenyl)-8-methyl-8-azabicyclo[3.2.1]octan-3-ol (102);

(1R,3r,5S)-3-(4-(1,4-dimethyl-2-(4-(methylsulfonyl)phenyl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-3-fluorophenyl)-8-isopropyl-8-azabicyclo[3.2.1]octan-3-ol (103);

1-(tert-butyl)-4-(4-(1,4-dimethyl-2-(4-(methylsulfonyl)phenyl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-2-fluorophenyl)piperidin-4-ol (104);

(R)-4-(4-(1,4-dimethyl-2-(4-(methylsulfonyl)phenyl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-2-fluorophenyl)-1-isopropyl-2,2-dimethylpiperidin-4-ol (105);

(S)-4-(4-(1,4-dimethyl-2-(4-(methylsulfonyl)phenyl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-2-fluorophenyl)-1-isopropyl-2,2-dimethylpiperidin-4-ol (106);

4-(4-(1,4-dimethyl-2-(4-(methylsulfonyl)phenyl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-2-fluorophenyl)-1-isopropylpiperidin-4-ol (107);

1-(tert-butyl)-4-(4-(1,4-dimethyl-2-(4-(methylsulfonyl)phenyl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-3-fluorophenyl)piperidin-4-ol (108);

4-(4-(1,4-dimethyl-2-(4-(methylsulfonyl)phenyl)-1H-pyrrolo[3,2-c]pyridin-6-yl)-3-fluorophenyl)-1-isopropylpiperidin-4-ol (109);

6-(4-(4-(4-iodophenethyl)piperazin-1-yl)phenyl)-1,4-dimethyl-2-(4-(methylsulfonyl)phenyl)-1H-pyrrolo[3,2-c]pyridine (110);

6-(4-(4-(4-bromophenethyl)piperazin-1-yl)phenyl)-1,4-dimethyl-2-(4-(methylsulfonyl)phenyl)-1H-pyrrolo[3,2-c]pyridine (111);

6-(4-(4-(4-iodobenzyl)piperazin-1-yl)phenyl)-1,4-dimethyl-2-(4-(methylsulfonyl)phenyl)-1H-pyrrolo[3,2-c]pyridine (112);

6-(4-(4-(4-bromobenzyl)piperazin-1-yl)phenyl)-1,4-dimethyl-2-(4-(methylsulfonyl)phenyl)-1H-pyrrolo[3,2-c]pyridine (113);

6-(1-(8-isobutyl-8-azabicyclo[3.2.1]octan-3-yl)piperidin-4-yl)-1,4-dimethyl-2-(4-(methylsulfonyl)phenyl)-1H-pyrrolo[3,2-c]pyridine (114);

4-(4-(4-(3-fluoro-1,4-dimethyl-2-(4-(methylsulfonyl)phenyl)-1H-pyrrolo[3,2-c]pyridin-6-yl)benzyl)piperazin-1-yl)-2-methylbutan-2-ol (115);

4-[4-[[4-[1-cyclopropyl-4-methyl-2-(4-methylsulfonylphenyl)pyrrolo[3,2-c]pyridin-6-yl]phenyl]methyl]piperazin-1-yl]-2-methyl-butan-2-ol (116);

4-[4-[[4-[1-(difluoromethyl)-4-methyl-2-(4-methylsulfonylphenyl)pyrrolo[3,2-c]pyridin-6-yl]phenyl]methyl]piperazin-1-yl]-2-methyl-butan-2-ol (117);

2-[6-[4-(4-isopropylpiperazin-1-yl)phenyl]-1-methyl-2-(4-methylsulfonylphenyl)pyrrolo[3,2-c]pyridin-4-yl]propan-2-ol (118);

6-[4-(4-isopropylpiperazin-1-yl)phenyl]-4-methoxy-1-methyl-2-(4-methylsulfonylphenyl)pyrrolo[3,2-c]pyridine (119);

4-[6-[4-(4-isopropylpiperazin-1-yl)phenyl]-1-methyl-2-(4-methylsulfonylphenyl) pyrrolo[3,2-c]pyridin-4-yl]morpholine (120);

1-[3-[[4-[1-cyclopropyl-2-(4-methylsulfonylphenyl)pyrrolo[3,2-c]pyridin-6-yl] phenyl]methyl]-3,8-diazabicyclo[3.2.1]octan-8-yl]-2-methyl-propan-2-ol (121);

1-(4-(4-(3-fluoro-1,4-dimethyl-2-(4-(methylsulfonyl)phenyl)-1H-pyrrolo[3,2-c] pyridin-6-yl)benzyl)piperazin-1-yl)-2-methylpropan-2-ol (122);

1-(4-(4-(1-cyclopropyl-4-methyl-2-(4-(methylsulfonyl)phenyl)-1H-pyrrolo[3,2-c] pyridin-6-yl)benzyl)piperazin-1-yl)-2-methylpropan-2-ol (123);

1-(4-(4-(1-(difluoromethyl)-4-methyl-2-(4-(methylsulfonyl)phenyl)-1H-pyrrolo[3,2-c] pyridin-6-yl)benzyl)piperazin-1-yl)-2-methylpropan-2-ol (124);

2-(6-(4-((4-isopropylpiperazin-1-yl)methyl)phenyl)-1-methyl-2-(4-(methylsulfonyl) phenyl)-1H-pyrrolo[3,2-c]pyridin-4-yl)propan-2-ol (125);

6-(4-((4-isopropylpiperazin-1-yl)methyl)phenyl)-4-methoxy-1-methyl-2-(4-(methylsulfonyl)phenyl)-1H-pyrrolo[3,2-c]pyridine (126);

4-(6-(4-((4-isopropylpiperazin-1-yl)methyl)phenyl)-1-methyl-2-(4-(methylsulfonyl) phenyl)-1H-pyrrolo[3,2-c]pyridin-4-yl)morpholine (127);

1-(4-(4-(1-cyclopropyl-2-(4-(methylsulfonyl)phenyl)-1H-pyrrolo[3,2-c]pyridin-6-yl) benzyl)piperazin-1-yl)-2-methylpropan-2-ol (128);

4-(4-(4-(1-cyclopropyl-2-(4-(methylsulfonyl)phenyl)-1H-pyrrolo[3,2-c]pyridin-6-yl) benzyl)piperazin-1-yl)-2-methylbutan-2-ol (129); or

1-(8-(4-(1-cyclopropyl-2-(4-(methylsulfonyl)phenyl)-1H-pyrrolo[3,2-c]pyridin-6-yl) benzyl)-3,8-diazabicyclo[3.2.1]octan-3-yl)-2-methylpropan-2-ol (130).

10. A pharmaceutical composition comprising one or more compounds according to any one of claims 1 to 9 or stereoisomers, tautomer, solvates or pharmaceutically-acceptable salts thereof; and a pharmaceutically acceptable carrier.

11. A compound according to any one of claims 1 to 9 or stereoisomers, tautomers, solvates or pharmaceutically-acceptable salts thereof, for use in treating pathological fibrosis.

12. The compound or stereoisomers, tautomers, solvates or a pharmaceutically-acceptable salt thereof, or pharmaceutically-acceptable salts thereof, for use according to claim 11 wherein said pathological fibrosis is liver fibrosis, renal fibrosis, biliary fibrosis, or pancreatic fibrosis.

13. A compound according to any one of claims 1 to 9 or stereoisomers, tautomers, solvates or pharmaceutically-acceptable salts thereof, for use in treating nonalcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), chronic kidney disease, diabetic kidney disease, primary sclerosing cholangitis (PSC), or primary biliary cirrhosis (PBC).

14. A compound according to any one of claims 1 to 9 or stereoisomers, tautomers, solvates or pharmaceutically-acceptable salts thereof, for use in treating idiopathic pulmonary fibrosis (IPF).

15. Use of the compound according to any one of claims 1 to 9 or stereoisomers, tautomers, solvates or pharmaceutically-acceptable salts thereof, in the manufacture of a medicament for treating pathological fibrosis.

16. The use according to claim 15, wherein said pathological fibrosis is liver fibrosis, renal fibrosis, biliary fibrosis, or pancreatic fibrosis.

17. Use of the compound according to any one of claims 1 to 9 or stereoisomers, tautomers, solvates or pharmaceutically-acceptable salts thereof, in the manufacture of a medicament for treating nonalcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), chronic kidney disease, diabetic kidney disease, primary sclerosing cholangitis (PSC), or primary biliary cirrhosis (PBC).

18. Use of the compound according to any one of claims 1 to 9 or stereoisomers, tautomers, solvates or pharmaceutically-acceptable salts thereof, in the manufacture of a medicament for treating idiopathic pulmonary fibrosis (IPF).

19. A compound according to any one of claims 1 to 9 or stereoisomers, tautomers, solvates or pharmaceutically-acceptable salts thereof, for use in therapy.